Laboratory Co. of America Holdings (NYSE:LH) Shares Bought by Unison Advisors LLC

Unison Advisors LLC boosted its position in Laboratory Co. of America Holdings (NYSE:LHFree Report) by 0.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,053 shares of the medical research company’s stock after purchasing an additional 51 shares during the period. Unison Advisors LLC’s holdings in Laboratory Co. of America were worth $2,415,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP raised its holdings in Laboratory Co. of America by 20.6% during the third quarter. Wellington Management Group LLP now owns 2,487,106 shares of the medical research company’s stock worth $500,033,000 after purchasing an additional 424,684 shares during the last quarter. Morgan Stanley raised its holdings in shares of Laboratory Co. of America by 102.6% in the third quarter. Morgan Stanley now owns 2,219,291 shares of the medical research company’s stock worth $446,189,000 after acquiring an additional 1,123,755 shares during the last quarter. Lazard Asset Management LLC raised its holdings in shares of Laboratory Co. of America by 28.0% in the third quarter. Lazard Asset Management LLC now owns 2,212,497 shares of the medical research company’s stock worth $444,821,000 after acquiring an additional 483,878 shares during the last quarter. Norges Bank acquired a new position in shares of Laboratory Co. of America in the fourth quarter worth $291,045,000. Finally, Northern Trust Corp raised its holdings in shares of Laboratory Co. of America by 3.0% in the fourth quarter. Northern Trust Corp now owns 1,163,252 shares of the medical research company’s stock worth $264,396,000 after acquiring an additional 33,493 shares during the last quarter. 95.94% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Laboratory Co. of America

In related news, COO Mark S. Schroeder sold 6,477 shares of Laboratory Co. of America stock in a transaction on Monday, April 1st. The shares were sold at an average price of $217.29, for a total transaction of $1,407,387.33. Following the transaction, the chief operating officer now owns 5,036 shares in the company, valued at approximately $1,094,272.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 250 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $204.13, for a total value of $51,032.50. Following the transaction, the director now owns 15,972 shares in the company, valued at approximately $3,260,364.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Mark S. Schroeder sold 6,477 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $217.29, for a total transaction of $1,407,387.33. Following the completion of the transaction, the chief operating officer now owns 5,036 shares in the company, valued at approximately $1,094,272.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,469 shares of company stock worth $3,959,058. 0.85% of the stock is currently owned by corporate insiders.

Laboratory Co. of America Trading Down 0.2 %

Shares of NYSE LH traded down $0.43 during trading on Tuesday, hitting $207.57. 21,262 shares of the company traded hands, compared to its average volume of 745,602. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $234.09. The company has a 50-day moving average price of $201.92 and a 200-day moving average price of $213.24. The firm has a market capitalization of $17.50 billion, a P/E ratio of 41.85, a P/E/G ratio of 1.54 and a beta of 1.05. The company has a quick ratio of 0.76, a current ratio of 0.88 and a debt-to-equity ratio of 0.39.

Laboratory Co. of America (NYSE:LHGet Free Report) last posted its earnings results on Thursday, April 25th. The medical research company reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.20. The business had revenue of $3.18 billion for the quarter, compared to analyst estimates of $3.12 billion. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.82 EPS. On average, equities analysts predict that Laboratory Co. of America Holdings will post 14.87 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 12th. Investors of record on Tuesday, May 28th were issued a dividend of $0.72 per share. The ex-dividend date was Friday, May 24th. This represents a $2.88 annualized dividend and a dividend yield of 1.39%. Laboratory Co. of America’s payout ratio is 57.95%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on LH. Barclays cut their price target on Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. JPMorgan Chase & Co. cut their price target on Laboratory Co. of America from $261.00 to $243.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. StockNews.com downgraded Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Tuesday, June 4th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Laboratory Co. of America in a research report on Monday, February 26th. Finally, Truist Financial lowered their price objective on Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, April 26th. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.86.

Read Our Latest Stock Report on LH

About Laboratory Co. of America

(Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).

Recommended Stories

Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.